Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

The Effects of Gonadotropin-Releasing Hormone Agonists on Final Height and its Related Factors in Patients with True Precocious Puberty

진성 성조숙증 환아에서 Gonadotropin-Releasing Hormone Agonists의 치료가 최종 성인 신장에 미치는 영향 및 이와 관련된 인자들에 관한 연구

An, Seong-Yeon;Ryu, Jae-Ho;Sin, Chung-Ho;Yang, Se-Won
안성연;류재호;신충호;양세원

  • Published : 20040000
⟨ Previous Next ⟩

Abstract

Purpose:The aim of this study was to evaluate the effects of treatment with GnRH agonists on final height(FH) and the influencing factors on height gains. Methods:Twenty-five girls and five boys with true precocious puberty, who were treated with GnRH agonists for more than one year and had attained final height, were evaluated retrospectively. We analysed auxological parameters at diagnosis, at the end of treatment, and at the attainment of final height, and calculated height gains. Results:FH SDS was significantly higher than predicted adult height(PAH) SDS at diagnosis (-0.91±1.32, vs. -1.80±1.39, P<0.01). A group of initial PAH below the range of target height(TH) attained significantly more height gains and increments of height SDS than those in a group of initial PAH within the range of TH(8.37±2.56 cm vs. 1.38±6.42 cm, P<0.01; 1.30±0.74 vs. 0.35±1.28, P<0.05). Height gains were positively correlated with bone age advancement at diagnosis and height velocity during the first year of treatment(r=0.528, P<0.01 and r=0.454, P<0.05), while height gains were negatively correlated with initial PAH and bone age increments during treatment(r=-0.485, P< 0.05 and r=-0.613, P<0.01). Conclusion:This study suggests that GnRH agonist therapy for children with true precocious puberty improves the final height, and height gains are positively affected by bone age advancement at diagnosis and growth velocity during the first year of therapy, and negatively affected by PAH at diagnosis and degree of bone maturation during therapy

Keywords

References

  1. Ojeda SR, Heger S. New thoughts on female precocious puberty. J Pediatr Endocrinol Metab 2001;14:245-56
  2. Bassi F, Bartolini O, Neri AS, Gheri RG, Bucciantini S, Cheli D, et al. Precocious puberty:auxological criteria discriminating different forms. J Endocrinol Invest 1994;17: 793-7
  3. Pasquino AM, Cives C, Maciocci M, Tebaldi L, Musleh M, Boscherini B. Transient true precocious puberty. A report of five cases. Eur J Pediatr 1989;148:735-6
  4. Fontoura M, Brauner R, Prevot C, Rappaport R. Precocious puberty in girls:early diagnosis of a slowly progressing variant. Arch Dis Child 1989;64:1170-6
  5. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls:initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999;84:415-23
  6. Rosenfield RL. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr 1994;124:989-91
  7. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405
  8. Kappy MS, Ganong CS. Advances in the treatment of precocious puberty. Adv Pediatr 1994;41:223-61
  9. Oerter KE, Manasco PK, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after long- term treatment with deslorelin. J Clin Endocrinol Metab 1991;73:1235-40
  10. Paul D, Conte FA, Grumbach MM, Kaplan SL. Long term effect of gonadotropin-releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995;80:546-51
  11. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Final height of girls with central precocious puberty, untreated vs. treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res 1997; 47:54-61
  12. Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr 1998;87:521-7
  13. Kreiter M, Burstein S, Rosenfield RL, Moll GW Jr, Cara JF, Yousefzadh DK, et al. Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 1990;117:364-70
  14. Ghirri P, Bottone U, Gasperi M, Bernardini M, Coccoli L, Giovanelli R, et al. Final height in girls with slowly progressive untreated central precocious puberty. Gynecol Endocrinol 1997;11:301-5
  15. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long- term treatment with LHRH agonists:the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86: 4711-6
  16. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty:final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583-90
  17. Antoniazzi F, Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, et al. End results in central precocious puberty with GnRH analog treatment:the data of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000;13(S1):773-80
  18. Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarre-van de Waal HA, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty:the Dutch experience. J Pediatr Endocrinol Metab 2000;13(S1):765-72
  19. Suh BK. Diagnosis and treatment of precocious puberty. J Korean Pediatr Soc 2001;44:607-13
  20. Oerter KE, Uriarte MM, Rose SR, Barnes KM, Cutler GB Jr. Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990;71:1251- 8
  21. Sonis WA, Comite F, Blue J, Pescovitz OH, Rahn CW, Hench KD, et al. Behavior problems and social competence in girls with true precocious puberty. J Pediatr 1985;106: 156-60
  22. Severi F, Burgio GR. Medroxyprogesterone acetate in the treatment of idiopathic precocious puberty. Padiatr Padol 1972;7:297-304
  23. Pasquino AM, Fraioli F, Iannetti P, Campea L, Carratu A, Boscherini B. Long-term treatment with medroxyprogesterone in 4 children with true precocious puberty. Minerva Pediatr 1976;28:517-25
  24. Comite F, Cutler GB Jr, Rivier J, Vale WW, Loriaux DL, Crowley WF Jr. Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. N Engl J Med 1981;305:1546-50
  25. Brauner R, Adan L, Malandry F, Zantleifer D. Adult height in girls with idiopathic true precocious puberty. J Clin Endocrinol Metab 1994;79:415-20
  26. Oostdijk W, Rikken B, Schreuder S, Otten B, Odink R, Rouwe C, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292-7
  27. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998;157: 363-7
  28. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty:importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973-8
  29. Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329-32
  30. Bouvattier C, Coste J, Rodrigue D, Teinturier C, Carel JC, Chaussain JL, et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty:a randomized long-term pilot study. J Clin Endocrinol Metab 1999;84: 3575-8
  31. Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with idiopathic central precocious puberty:implication for treatment. Clin Endocrinol 2002;56:297-302
  32. Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin- releasing hormone agonist treatment? J Pediatr 2000;137: 819-25
  33. Partsch CJ, Heger S, Sippell WG. Treatment of central precocious puberty:lessons from a 15 years prospective trial. German Decapeptyl Study Group. J Pediatr Endocrinol Metab 2000;13(S1):747-58
  34. Carel JC, Chaussain JL. Gonadotropin releasing hormone agonist treatment for central precocious puberty. Horm Res 1999;51(S3):64-9
  35. Ohyama K, Tanaka T, Tachibana K, Niimi H, Fujieda K, Matsuo N, et al. Timing for discontinuation of treatment with a long-acting gonadotropin-releasing hormone analog in girls with central precocious puberty. TAP-144SR CPP Study Group. Endocr J 1998;45:351-6